The 38th EACTS Annual Meeting | Daily News 11.10.24

Friday 11 October 2024

DAILY NEWS

Issue 2

The official newspaper of the 38th EACTS Annual Meeting 2024 PRESIDENTIAL ADDRESS

Join EACTS President, Franca Melfi, for an inspiring and motivating Presidential Address.

An inspirational leader and a true pioneer, she will use her speech to explore three key principles that for her sum up the never give up philosophy: perseverance, positivity and parity.

6 RESIDENTS' COMMITTEE

ADVANCING A CULTURE OF INNOVATION Today, EACTS is launching exciting new initiatives to drive advancements in cardiothoracic surgery and accelerate the adoption of disruptive technologies into clinical practice.

The Residents' Committee's programme features new interactive sessions and old favourites designed to encourage collaboration and communication.

7

The rise of artificial intelligence (AI) and synthetic biology will profoundly reshape our daily lives and revolutionise the field of medicine. These changes will be further amplified by breakthroughs in nanotechnology, quantum physics applications, robotics and nuclear fusion technology. To leverage these innovations and improve patient outcomes, EACTS has established a new Innovation Committee, an Innovation Hub and created new innovation and research grants.

TECHNO-COLLEGE INNOVATION AWARD

The Techno-College Innovation award recognises technological breakthroughs in all areas of thoracic and cardiovascular surgery. Learn more about this year's winner.

9

DAY 2 HIGHLIGHTS Highlights of the 2024 Innovation Summit – Part 1

Highlights of the 2024 Innovation Summit – Part 2

13:45 - 14:45

15:15 - 16:15

Auditorium 3+4

Auditorium 3+4

Edwards Lifesciences Lunch Symposium

New frontiers in mitral valve replacement Friday, October 11, 2024 12:15 - 13:30 | Auditorium 7 Edwards, Edwards Lifesciences and the stylized E logo are trademarks or service marks of Edwards Lifesciences Corporation. © 2024 Edwards Lifesciences Corporation. All rights reserved. NP--EU-2659 v1.0 Edwards Lifesciences Sàrl • Route de l’Etraz 70, 1260 Nyon, Switzerland • edwards.com

Chairs: Marjan Jahangiri

Vinod Thourani

Faculty:

Eduardo Saadi

Joerg Kempfert

Scan the QR code for more details

Marjan Jahangiri

Vinod Thourani

DAILY NEWS

IN THIS ISSUE

YOUR HIGHLIGHTS FROM THIS YEAR'S SCIENTIFIC PROGAMME

THE LATEST SCIENCE MOSLEM ABDELGHAFAR

There are over 170 focus and abstract sessions at the 38th EACTS Annual Meeting. Here we present summaries from a selection of today's presentations.

“This is my first EACTS Annual Meeting and I’ve enjoyed seeing the cutting-edge technology, whether it's cardiac, thoracic, congenital. I'm thoracic oriented, but I like to see what is happening in other areas of cardiothoracic surgery. There's also a lot of industry exhibitors, which are really valuable to see. It’s a very unique opportunity.

10

GIANTS IN THORACIC SURGERY

“It’s interesting to hear new research from every part of the world. I’ve heard presentations from Taiwan, China, Europe, United States.

Renown thoracic surgeon Valerie Rusch shares insights from her career.

12

“It's not just about the scientific content. It’s also about connecting with people colleagues, friends, and acquaintances from different countries.”

EXHIBITION

Visit the exhibition and keep up to date on the technologies that are transforming the everyday practice of cardiothoracic surgeons across the globe.

20

POSTERS

Enjoy even more science with moderated posters and e-poster discussions taking place today.

28

SATELLITE SYMPOSIA

Discuss current and future approaches and the latest clinical data in the wide range of satellite sessions hosted by industry.

ED LONG “The atmosphere is really nice and it’s great to meet people from all around the world to learn more about their experiences and discover new areas. It’s a great opportunity to hear more about new treatments and procedures that are not available in your home country. I’ve really enjoyed seeing the robotic technology and getting a glimpse of the future of cardiothoracic surgery.

“I am giving an oral presentation this year, so I am excited to be given a platform to share my research.”

31

DOWNLOAD THE EACTS APP HERE

A SNAPSHOT OF SOME OF TODAY'S SESSIONS 10:00 - 11:00 Navigating Excellence: Insights from the sky to the OR - Auditorium 3+4 (Interactive) 11:15 - 12:00 Presidential Address - Auditorium 1 13:45 - 14:45 Scalpel scars – Nightmares untold - Auditorium 1 16:30 - 17:30 EACTS/AATS Foundation Academic Excellence Award - Auditorium 3+4 (Interactive)

2

EACTS DAILY NEWS

Medtronic

Revolutionizing Cardiac Surgery: •

•

Precision I Re I abi 1ty, and nnovat1on •

Cutting-Edge Technology: Bio-Medicus Life Support™

is engineered for precision and reliability to ensure seamless integration into your surgical procedures, while providing the flexibility to treat each patient - smallest to largest, youngest to oldest.

Bio-Medicus ™ Life Support

Optimized Performance: Developed with extensive

user input, Bio-Medicus Life Support™ offers optimized flow dynamics and more catheter lengths, sizes, and configurations than any other brand out there.

Advanced Biocompatibility: Bio-Medicus Life Support™

catheters are made with Elast-Eon™ *, a biocompatible and biostable polyurethane/siloxane copolymer. 1 Elast-Eon™ * is commonly used in prolonged use and implantable medical devices.

Scan the QR code to learn more

Join the future of cardiac surgery

l

I

I

I

E l ,!

!

><

...I

>< QI LL

>< QI LL

'

l.

I c-

::e:I ::!!:

"

}s

I

'l

i ,i

ii

QI

E

rtJ

...

C

...I

....:I C

C

::!!:

::!!:

::!!:

>< ::e:I

�

rtJ "C

1. Bench data on file, may not be indicative of clinical performance. '"'Third-party brands are trademarks of their respective owners.

This material should not be considered the exclusive source of information, it does not replace or supersede information contained in the device manual(s). Please note that the intended use of a product may vary depending on geographical approvals. See the device manual(s) for detailed information regarding the intended use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For a MRI compatible device(s), consult the MRI information in the device manual(s) before performing a MRI. If a device is eligible for el FU usage, instructions for use can be found at Medtronic's website manuals.medtronic.com. Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat• Reader with the browser. Medtronic products placed on European markets bear the CE mark and the UKCA mark (if applicable). For any further information, contact your local Medtronic representative and/or consult Medtronic's websites.

2024-eacts-daily-journal-ad-en-gb-emea-14172982 © 2024 Medtronic. All rights reserved. Medtronic, Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic. All other brands are trademarks of a Medtronic company.

medtronic.eu

THURSDAYS HIGHLIGHTS

DAILY NEWS

LEARNING LABS Delegates had an opportunity to train with some of the world’s best cardiothoracic surgeons at the EACTS Learning Lab.

BIAS AND LEADERSHIP IN CARDIOTHORACIC SURGERY A focus session developed by the Women in Cardiothoracic Surgery Committee explored the inherent gender bias across the globe and provided useful insights on the challenges ahead.

4

EACTS DAILY NEWS

EACTS EXHIBITION Delegates packed the exhibition hall to forge new relationships and learn more about new-to-market technologies presented by industry.

DAILY NEWS 2024 UPDATED EACTS GUIDELINES Anders Jeppsson presenting at the guidelines session.

HONOURED GUEST Amy Kerdok shared her experiences of develeping user-centred medical products worldwide.

PRESIDENTIAL ADDRESS

THE POWER OF NEVER GIVING UP Auditorium / 11:15

EACTS President, Franca Melfi, will inspire you to never give up in this year’s Presidential Address. Plus there will be a surprise guest. Don’t miss out on this eagerly awaited session.

This year’s Presidential Address seeks to inspire and motivate you.

One of the highlights of the Annual Meeting is the Presidential Address which takes place this morning. Enrico Ruffini will introduce his friend and colleague, the brilliant Franca Melfi, and this introduction will touch on some of her many remarkable achievements.

Franca Melfi is an inspirational leader and a true pioneer.

She is the first woman to be the President of EACTS and is a strong proponent for the benefits of combining cardiac and thoracic to advance our learning and surgical skills.

Franca is Professor of Thoracic Surgery at the Medical School of the University of Pisa, but it is her pioneering use of robotics in lung surgery for which she receives international acclaim and is best known. As Chair of the Robotic Multidisciplinary Centre for Surgery – Thoracic MIS and Robotic surgery at the University Hospital of Pisa, she demonstrates the power of robotics not just for thoracic surgery, but for multiple specialties.

Technology provides some of the answers according to Franca. Our President is a tech pioneer and Franca will highlight that tech-based solutions are the enablers, providing the gateway for an exciting 'surgical democratisation’. The President will explain that technology can now accelerate our learning, helping the global cardiothoracic community enhance surgical skills across the world to deliver better outcomes for more patients far beyond Europe’s shores.

Franca is joined today by several EACTS members and colleagues from her team in Pisa where she has proudly developed a strong culture based on teamwork, advancement and effective communication to continually improve outcomes for patients.

As the first woman thoracic surgeon in Pisa, Franca has had to battle hard, overcoming numerous challenges to introduce new technologies. But, she will not dwell on personal milestones in her speech; rather she will highlight examples of how women have been incredibly successful, often against the odds, in the face of real adversity.

Franca’s ethos is to ‘never give up’ and she will use her speech to explore three key principles that for her sum up the never give up philosophy: perseverance, positivity and parity.

Whether you watch live in the auditorium or on EACTS TV, Franca will provide powerful stories to underpin her key themes, and a special guest will inspire you with her own journey, giving you plenty of ideas to take away with you after the Annual Meeting.

You will also be challenged. How do we ensure better outcomes for women patients? How do we address gender disparities in our specialty? How do we advance surgical skills across the world?

6

EACTS DAILY NEWS

As the first woman thoracic surgeon in Pisa, Franca has had to battle hard, overcoming numerous challenges to introduce new technologies.

Franca Melfi

Firsts for Franca Franca Melfi is a pioneer in the field.

1st

The 1st ever female President of EACTS

1st

The 1st person to use robotics in lung cancer surgery

1st

The 1st woman thoracic surgeon in Pisa

1st

The 1st surgeon in the world to perform robotic pulmonary lobectomies

1st

The 1st thoracic surgeon to perform in excess of 3,000 robotic thoracic procedures

1st

The 1st and so far the only person to lead Europe’s largest public robotic surgery centre in Pisa, training surgeons of the future

RESIDENTS' COMMITTEE

RESIDENTS’ COMMITTEE STILL TO COME...

Friday 11 October

Navigating Excellence: Insights from the sky to the OR 10:00 - 11:00 / Auditorium 3+4 Grab your boarding pass and climb aboard for an exciting new addition to this year’s scientific programme. Join Ryanair pilots, Martin Masat and Anna Modos, as they explore the intriguing parallels between aviation and cardiothoracic surgery. Hear more from Shirin Bemelmans-Lalezari as she shares her tips for integrating nontechnical skills into everyday practice.

EACTS RESIDENTS' COMITTEE

The EACTS Residents’ Committee has planned a captivating programme for this year’s EACTS Annual Meeting, comprising new sessions and old favourites.

Yesterday’s residents’ lunch kicked off the programme, giving residents the opportunity to debate key issues ranging from congenital heart disease to robotics with peers and senior surgeons in an informal setting.

CT Surgery Resident Showdown: Live European Final!

12:15 - 13:00 / TV Studio Watch as three outstanding teams go head-to-head in an electrifying competition that promises to be as informative as it is entertaining for the chance to compete for the title of CT Surgery Resident World Champion.

Scalpel scars - Nightmares untold 13:45 - 14:45 / Main Auditorium Join experienced residents and senior surgeons as they discuss three cases that didn’t go to plan.

Nabil Hussein says, “This is not a platform for the senior surgeon to showcase their achievements, but an important dialogue about the reality of surgical practice. It’s important to recognise that each of these accomplished professionals faced challenges during their training, and learning from them led them to where they are today.

“This session provides a valuable opportunity to observe how experienced surgeons resolve these challenges in a friendly, supportive environment.”

Saturday 12 October

From incision to emission – a sustainable future 08:30 - 09:30 / Auditorium 3+4

Residents were faced with navigating challenging cases in acquired cardiac, congenital and thoracic surgery alongside peers in a highly collaborative session ‘Escape the Coffin’.

“This interactive session offered an exhilarating escape-room experience that immersed the audience in a seemingly ordinary day in the life of a resident. However, as the day unfolded, a series of unexpected challenges arose, and it was up to the audience to vote on which treatment steps to take” explains Nabil Hussein, Chair of the Residents’ Committee.

New for 2024 is a compelling session on the importance of sustainability. Cardiothoracic surgery has a huge impact on the environment, and we’re keen to address what we can do to reduce our carbon footprint. Join the Residents’ Committee for a future-focused session looking at how we can work towards a more sustainable approach to our everyday practice.

“This collaborative session fosters teamwork and communication by providing a dynamic learning environment that encourages audiences to share their expertise.”

Issue 2 Friday 11th October

7

Artivion’s

Aortic Clinical At Artivion, we partner with cardiovascular surgeons to develop cutting-edge technologies to treat patients with aortic diseases. We are committed to collecting and sharing clinical data related to our aortic-centric technologies to further the science of treating aortic disease.

Check out our most recent clinical data releases.

On-X® Aortic Post Approval Study 5-Year Results On-X®

87 % Lower Bleeding Risk On-X® Aortic is the ONLY mechanical valve available with 87 % lower bleeding risk and 50 % lower INR.1

PERSEVERE US IDE Study 30-Day Results 9.7 % 30-Day Mortality in Patients with ADTI Complicated by Malperfusion

AMDS™

The PERSEVERE IDE Trial demonstrated a significantly lower 30-day mortality rate of 9.7 % in patients with Acute DeBakey Type I (ADTI) dissection complicated by malperfusion treated with the AMDS™ device, compared to a Hemiarch alone reference cohort.2

NEOS Registry Interim Results E-vita® Open Neo

5.1 % Low 30-Day Mortality Rate Interim results from the NEOS Registry showed a low 30-day mortality rate of 5.1 % with E-vita® Open Neo compared to other FET devices (up to 10 %) with comparable secondary outcomes.3

TRIOMPHE US IDE Study 30-Day Results 0 % Low Disabling Stroke Rate

NEXUS®

The 30-day data for the first 22 patients showed a low mortality rate and no disabling strokes, paraplegia, or renal failure.4

References: 1. Gerdisch, M. W., Hagberg, R. C., Perchinsky, M. J., Joseph, M., Oo, A. Y., Loubani, M., Tsang, G. M., Zacharias, J., & Sathyamoorthy, M. (2024). Low-dose warfarin with a novel mechanical aortic valve: Interim registry results at 5-year follow-up. The Journal of thoracic and cardiovascular surgery, S0022-5223(24)00359-3. Advance online publication. https://doi.org/10.1016/j.jtcvs.2024.04.017. 2. Szeto, W.Y. et al. (2024) ‘A novel hybrid prosthesis for open repair of acute debakey type I dissection with malperfusion: Early results from the persevere trial’, The Journal of Thoracic and Cardiovascular Surgery [Preprint]. doi:10.1016/j.jtcvs.2024.07.059. 3. Mousavizadeh et al., 2022; Papakonstantinou et al., 2019; Tian et al., 2020; Nakhaei et al., 2022; Rezaei et al., 2021; Ferreira et al., 2022; Hanif et al., 2018; Harky et al., 2020; Preventza et al., 2020; Smith et al., 2017; Akbulut et al., 2019; Jakob et al., 2017; Widenka et al., 2022; Akbulut et al., 2020; Liebrich et al., 2021. 4. Leshnower, B; Late-Breaking: Early Results from the TRIOMPHE IDE Study: Zone 0 Endovascular Aortic Arch Repair Using an Off the Shelf Single Branch Device. STS Annual Meeting, Jan 27–29, 2024; San Antonio, TX. Except as otherwise noted, all trademarks are owned by Artivion, Inc. or its subsidiaries. Not all products and indications are available or approved in all markets. Caution: The AMDS™ Hybrid Prothesis and NEXUS® are approved as Investigational Devices only and not for commercial use in the United States. The NEXUS® Aortic Arch System is manufactured by Endospan Ltd. and distributed by Artivion. NEXUS is a registered trademark of Endospan Ltd. All other trademarks are owneds by Artivion, Inc. or its subsidiaries. On-X Life Technologies, Inc., Jotec GmbH, and Ascyrus Medical GmbH are wholly owned subsidiaries of Artivion, Inc. © 2024 Artivion, Inc. All rights reserved.

JOTEC GmbH, Lotzenäcker 23, 72379 Hechingen, Germany, is the manufacturer of E-vita® Open Neo Hybrid Stent Graft System Ascyrus Medical GmbH, Grosse Gallusstrasse 16-18, 60312 Frankfurt, Germany, is the manufacturer of AMDS™ Hybrid Prosthesis On-X Life Technologies, 1300 East Anderson Lane, Bldg B, Austin, TX 78752, USA, is the manufacturer of On-X® Heart Valves Endospan Ltd, Maskit St. 4, Herzlia Business Park, Herzlia 46733, Israel, is the manufacturer of Nexus® Aortic Arch Stent Graft System

MLENG1812.000 (2024-09)

INNOVATION

TECHNO-COLLEGE INNOVATION AWARD The Techno-College Innovation award recognises technological breakthroughs in all areas related to thoracic and cardiovascular research in particular for new surgical methods or devices. Ahmad Ali Amirghofran from the Shiraz University of Medical Sciences in Iran was awarded the 2024 TechnoCollege Innovation award in recognition of the SRAA valve, a stented Biologic Valve with the Native Right Atrial Appendage Tissue.

Cardiac surgeons aim to develop heart valves without the drawbacks of mechanical and biological valves because both options come with significant limitations. Using native tissue valves, which are crafted from the patient’s own tissues or engineered to closely mimic them, could offer a solution by providing a more natural, durable, and compatible replacement.

This would eliminate the need for anticoagulation, reduce the risk of immune rejection, and promote better healing, improving patient outcomes and quality of life.

To create an effective native tissue heart valve, two main factors are crucial. First, the tissue used must have the appropriate biological and mechanical properties to function like a natural heart valve. This means the tissue should be strong, flexible, and capable of withstanding the repetitive stresses of the cardiovascular system. Second, a welldesigned, architecturally sound skeleton, or scaffold, is needed to support this tissue. The scaffold must provide the geometric shape and structure for the valve, ensuring proper function. Both the tissue and the scaffold must work together to mimic the complex dynamics of natural valve function.

Using the right atrial appendage tissue to create native heart valves, particularly for the right side of the heart, is a promising approach based on our extensive six-year experience with over 200 patients, where the RAA valve was used to replace the pulmonic valve. The right atrial appendage tissue seems to offer the necessary flexibility, strength, and compatibility with the patient's own body, which helps to minimise the risk of immune based rejection and degeneration with no need for anticoagulation. This approach may lead to improved patient outcomes, fewer complications, and greater long-term durability for rightsided heart valve replacements.

We are currently expanding our work to develop native tissue valves for the higher-pressure left-sided heart valves, such as the aortic and mitral valves, by exploring the use of different tissue types, including the pericardium. This tissue has the potential to withstand the higher mechanical stresses experienced on the left side of the heart.

In addition to refining tissue selection, we are evaluating different valve designs, specifically comparing the trileaflet design with the bicuspid one. The trileaflet design closely mimics the natural structure of human heart valves, potentially offering more efficient blood flow and reduced stress on the valve. However, the simpler bicuspid design could offer advantages in terms of durability and ease of implantation. By carefully analysing these factors, we aim to optimise both the tissue and design to ensure long-term function and durability in left-sided valve replacements.

The key breakthrough in the development of native tissue cardiac valves lies in the design of a 3D stent or frame, which serves as the foundational skeleton for supporting the valve's function. This innovative framework, referred to as the "Shiraz frame," provides a versatile and durable structure that can be made available in various sizes to accommodate different patients' anatomical needs.

During surgery, the native tissue is mounted onto this frame and tailored intraoperatively to create a functional, stented native valve. This approach combines the natural advantages of the patient’s own tissue with the precision of engineered support, offering a more adaptable, durable, and biocompatible solution for heart valve replacement, and potentially transforming outcomes for patients.

Next steps In our recent clinical experience, we have successfully used both stented and non-stented right atrial appendage (RAA) valves for tricuspid and pulmonary valve replacements in seven patients, achieving excellent immediate and shortterm outcomes. Echocardiographic studies have confirmed that the valves function perfectly and remain stable, with no reported complications to date.

We have also developed the Shiraz frame in various sizes, making it readily available for use during surgery.

In the second generation of this frame, we introduced two key modifications that allow for future valve-in-valve transcatheter valve implantation in case the native tissue valve shows signs of dysfunction. This advancement enhances both the safety and long-term durability of using these native tissue valves.

The Techno-College Innovation Award The Techno-College Innovation award highlights the potential of the SRAA valve to transform how we approach heart valve replacements, particularly by offering a native tissue-based solution that addresses many of the challenges associated with traditional mechanical and biological valves.

It means that the SRAA valve is gaining attention within the medical community, validating its effectiveness and safety, and opening the door for further research and broader clinical adoption. Ultimately, this recognition brings us one step closer to improving outcomes for patients worldwide and making native tissue valves a viable option for heart valve replacement.

The finalists of this year's Techno-College Innovation award are Min-Woong Kang and Ana Martins Costa.

Issue 2 Friday 11th October

9

EACTS/STS SESSION

Alessandro Della Corte Associate Professor of Cardiac Surgery University of Campania, Naples, Italy

Auditorium 7 / 10:00 - 11:00

My presentation will provide food for thought about what is new and what is different in the recommendations for the surgical treatment of proximal aorta aneurysm in patients with bicuspid aortic valve (BAV), using clinical cases to illustrate this. In particular, I will focus on the new factors (or “high-risk features”) that need to be considered along with the diameter in risk stratification for acute aortic events in decision-making about surgical treatment of the ascending aorta/aortic root.

BAV aortopathy has long been associated with a significant increase in the risk of acute type A aortic dissection, however the gaps in knowledge on the pathogenetic mechanisms has led to wavering guidelines. Clinical research performed

EACTS/STS SESSION: HOW DID THE 2023 EACTS/STS AORTIC GUIDELINES CHANGE YOUR PRACTICE? A CASED-BASED DISCUSSION BY THE EXPERTS Aortic aneurysm in patients with bicuspid aortic valve The new EACTS/STS Guidelines for diagnosing and treating acute and chronic syndromes of the aortic organ have introduced a number of new or revised recommendations in the area of surgical indication criteria and thresholds for dilatation of the proximal aorta (root and ascending).

ACCREDITATION

EARN YOUR CREDITS Participants will be awarded credits for time spent in sessions – don’t forget to scan your badge when you enter a session room to record your participation.

EACCME Accreditation The 38th EACTS Annual Meeting, Lisbon, Portugal 09/10/2024 – 12/10/2024, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 24.0 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits(TM).

10

EACTS DAILY NEWS

Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications “Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.”

during the last decade has led to new understanding and to the development of new recommendations (AATS consensus guidelines 2018) and a new nomenclature (2021 consensus document on nomenclature and classification of the BAV and its aortopathy). Very recent evidence suggests that this has impacted the natural history of bicuspid aortopathy, reducing the gap with the general population in terms of risk of dissection.

The new guidelines, therefore, extended the principles of more articulated risk stratification and more personalised treatment criteria to the tricuspid-associated aortopathies too (Figure).

FOCUS SESSION

Alexander Jánosi West German Heart and Vascular Center (WHGZ)

Room 3B, Pav 3 / 13:45 - 14:45

KNOWLEDGE EVERY CARDIAC SURGEON SHOULD HAVE PRIOR TO PERFORMING A CABG: CLARIFYING THE CONCEPTS OF CORONARY ISCHEMIA, REVERSIBILITY AND REGIONAL MYOCARDIAL PERFUSION

Understanding the differences between IFR-FFR and their impact on PCI and CABG There are some important differences between Instant Wave-Free Ratio (iFR) and Fractional Flow Reserve (FFR), and their respective impacts on percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). Both iFR and FFR are crucial physiological indices used to assess the severity of coronary artery stenosis. While FFR requires inducing hyperemia using adenosine to measure pressure differences across a coronary lesion, iFR does not, offering a faster and more comfortable procedure for patients.

FFR has demonstrated its value in guiding PCI by optimising decision-making on whether to stent or not, leading to improved clinical outcomes and costeffectiveness. However, the role of FFR in CABG is still under investigation. Several studies indicate that FFR can simplify surgical strategies by reducing unnecessary grafts, particularly when used to avoid bypassing functionally insignificant stenoses, thus improving arterial graft patency. However, concerns remain about its ability to prevent long-term complications such as graft failure, and the potential risk of undermining the traditional protective benefits of CABG, such as distal revascularisation and collateralisation.

This presentation will delve into current evidence on the utilisation of both indices, exploring their physiological basis, clinical applications, and the evolving understanding of their roles in coronary revascularisation strategies.

FFR has demonstrated its value in guiding PCI by optimising decisionmaking on whether to stent or not, leading to improved clinical outcomes and cost-effectiveness.

FOCUS SESSION

Join the conversation across our social media channels #EACTS2024

FOCUS SESSION A life and career in thoracic surgery Valerie Rusch Thoracic Surgeon, Memorial Sloan Kettering Cancer Center, New York

GIANTS IN THORACIC SURGERY

A special focus session this afternoon features three true giants of thoracic surgery. We are delighted to welcome Valerie Rusch, a world-renowned thoracic surgeon from the US, who will share some of the highlights from her distinguished career, as well as experienced thoracic surgeon, Alper Toker, and former EACTS President, Peter Licht, who will both present a challenging case from their careers.

What’s your assessment of the female/male ratio in the operating room?

The era in which I trained and became board certified there were very few women in the profession. I believe I was only the 21st woman thoracic surgeon to be certified by the American Board of Thoracic Surgery back in 1983. Throughout my career I have certainly had the experience of being the only woman in the room. I grew up in an era where there were very few women performing surgery.

This is changing gradually. The percentage of women who do cardiac surgery is still in the single digits in the US. The percentage of women who do general thoracic surgery is somewhat higher at around 15%. However, we are seeing higher numbers of women trainees. I’m not sure we have quite reached the tipping point, but it has certainly evolved significantly, particularly over the past decade.

What advice would you give to cardiothoracic surgeons at the start of their career?

I think it’s helpful to identify mentors with whom you can talk as you progress through your education and training. They may be men or women, and they may or may not be cardiothoracic surgeons. I’ve had mentors during my career from other specialties. You look for mentors who can help you with life skills, work-life balance and those kinds of issues.

You look for clinical mentors who can help you grow in your clinical practice. And you look for academic mentors who can help you evolve in and succeed in academic research.

The other important issue to understand for both men and women, and particularly for women, is that it’s very challenging to have it all. It is difficult to achieve a work life balance in a specialty that is time and labour intensive and so unpredictable in terms of schedule. You need to build an infra-

structure that supports both family and career. It’s important to be realistic about the needs of your career and the needs of your family and try to balance those and not get burnt out.

How do you see the future of cardiothoracic surgery?

For both cardiac and thoracic surgery, we are in an era that is very exciting. We are at the intersection of rapid evolution in technology and basic biology – whether that’s tumour biology or cardiovascular biology. There is evolution in what we can do in the operating room, in how we evaluate our patients preoperatively and in multidisciplinary care. It is an exciting time with tremendous opportunities – intellectually, clinically and scientifically. It is a very vibrant specialty.

I think it’s helpful to identify mentors with whom you can talk as you progress through your education and training. They may be men or women, and they may or may not be cardiothoracic surgeons.

FOCUS SESSION

FOCUS SESSION Figure 2: TAVR in TAVR explant and aortic valve replacement

Derrick Tam & Alfredo Trento Cedars-Sinai Medical Center

Room 5A, Pav 5 / 16:30 - 17:30

TAVR OR SAVR? SURGICAL CHALLENGES IN LIFETIME MANAGEMENT

Overall, we showed that early and late mortality was low in patients undergoing TAVR explant by experienced surgeons at high volume centers, highlighting the potential need to centralise care for this high risk and complex procedure.

Figure 1: Double instrument technique to help explant TAVR valves.

Transcatheter aortic valve explant experience from a high volume surgical structural heart centre When transcatheter aortic valve replacement (TAVR) fails and repeat TAVR is not possible, TAVR explant remains a viable strategy yet results from multicentre studies have shown high morbidity (up to 75% early complication rate) and mortality (15-20% at 30-days). The aim of this project is to examine early and late outcomes after TAVR explant at a high-volume TAVR center (> 600 TAVR per year). The Society of Thoracic Surgeons registry was queried to identify all patients undergoing aortic valve replacement with a history of previous TAVR valve from 2011 to 2023.

Institutional trends, operative outcomes, and survival at 30-days and 5-years were compared between TAVR explant and isolated surgical aortic valve replacement (SAVR) and concomitant SAVR with other procedures.

The number of TAVR and TAVR explants increased significantly throughout the study. The median time to TAVR explant was 400 days. The 30-day mortality (6.8%) and 30-day mortality and morbidity (27%) were low despite high rates of concomitant procedures (70%).

The addition of concomitant procedures to SAVR at time of TAVR explant did not worsen early (30-day mortality: 0% vs 9.7%, p = 0.613) or late (5-year survival: HR 1.05, 95%CI 0.23- 3.87, p = 0.945) outcomes.

Overall, we showed that early and late mortality was low in patients undergoing TAVR explant by experienced surgeons at high volume centers.

FOCUS SESSION

Thank you to our social media ambassadors for the 38th EACTS Annual Meeting.

Your efforts in highlighting the latest from Lisbon and keeping the conversation going before, during, and beyond #EACTS2024 have been invaluable.

Issue 2 Friday 11th October

13

FOCUS SESSION This talk is divided into three main sections: 1) Dissection techniques and tips, 2) Augmentation of stenotic MAPCAs, and 3) Unifocalisation strategies and techniques.

Richard D. Mainwaring Stanford University School of Medicine

Auditorium 6 / 13:45 - 14:45

The final portion of the talk will review our analysis of the fate of unifocalised MAPCAs. This analysis demonstrated that 75% of unifocalised MAPCAs were widely patent, 20% had some stenosis, and 5% were occluded. The majority of stenotic unifocalised MAPCAs can be resuscitated using either interventional catheter techniques, surgical repair, or a combination of both. The techniques that we have developed for surgical revision of unifocalised MAPCAs are summarised in this talk.

The majority of stenotic unifocalised MAPCAs can be resuscitated using either interventional catheter techniques, surgical repair, or a combination of both.

AVOIDING STENOSES IN THE PULMONARY ARTERIES IN SURGERY FOR CONGENITAL HEART DISEASE HOW TO AVOID STENOSIS OF MAPCAs Midline unifocalisation was developed by Dr. Frank Hanley for the treatment of pulmonary atresia with ventricular septal defect and major aortopulmonary collateral arteries (PA/VSD/MAPCAs). This approach has been shown to have low surgical mortality, high success in achieving complete repair, and low right ventricular pressures.

Implicit in achieving these results is the concept that the unifocalised MAPCAs are patent and free of stenosis in order to provide unobstructed pulmonary blood flow. The purpose of this talk will be to review strategies for avoiding stenosis of MAPCAs.

FOCUS SESSION

DON'T MISS...

Late Breaking Science: Coronary Artery Bypass Grafting and Perioperative Care 15:15 - 16:15 Auditorium Don't miss this late breaking science session which includes a presentation on 'personalised multimodal teleprehabilitation in elective cardiac surgery'. The manuscript for this late breaking trial has been accepted by JACC for simultaneous publication today.

GENERAL ASSEMBLY All EACTS members welcome Friday 11 October 17:45-18:30 / Auditorium 2

This marks the first time a late breaking clinical trial presented at a cardiothoracic surgical meeting will be simultaneously published in a major cardiology journal!

Issue 2 Friday 11th October

15

SCIENTIFIC PROGRAMME PROGRAMME

THURSDAY 10 OCTOBER Auditorium 1

Auditorium 2

Auditorium 3+4

Auditorium 6

Auditorum7

Auditorium 8

Room 3A

Room 3B

Room 3C

Room 5A

Room 5B

08:30 – 09:30 President’s Choice, Auditorium 1 09:30 – 10:00 Moderated e-Posters, Theatres 1, 2, 3 & 4 10:00 – 11:00

10:00 – 11:00

10:00 – 11:00

10:00 – 11:00

10:00 – 11:00

10:00 – 11:00

10:00 – 11:00

10:00 – 11:00

10:00 – 11:00

10:00 – 11:00

10:00 – 11:00

Revolutions in coronary surgery

Cardiothoracic trauma

Late breaking science: aortic disease and transcatheter MVR

TGA with LVOTO

“Make the pain go away!” - left subclavian artery management during treatment of aortic arch diseases

Advancements in mechanical circulatory support and cardiac function

Access sites for TAVI – a step by step procedural guide

Bias and leadership in cardiothoracic surgery

Robotic coronary surgery: here to stay!

Gaps in knowledge in aortic regurgitation treatment in BAV

Unique techniques and development in neonatal and pediatric perfusion - joint EACTS/EBCP session

11:15 – 12:00 Honoured Guest, Auditorium 1 12:00 – 13:45 Lunch, Exhibition, Satellite Symposia, e-Poster discussions, Hall 1 & 2 13:45 – 14:45

13:45 – 14:45

13:45 – 14:45

13:45 – 14:45

13:45 – 14:45

13:45 – 14:45

13:45 – 14:45

13:45 – 14:45

13:45 – 14:45

13:45 – 14:45

13:45 – 14:45

2024 updated EACTS guidelines

Enlarging horizons in telemanipulation surgery

Ross procedure in patients with pure aortic regurgitation

New technologies, new techniques

Surgical or transcatheter treatment of recurrent mitral valve regurgitation?

A deep dive into acute aortic dissection

The role of local heart teams in deciding the most appropriate revascularisation strategy for each individual patient with obstructive coronary artery disease: from guidelines to the real world

Tricuspid disease: once forgotten, now all the rage

New methodologies in organ preservation, xenotransplantation and use of marginal organs in the management of advance heart failure

Not guilty your honour – the importance of medicolegal aspects of cardiothoracic surgery

Aortic root surgery in Marfans

14:45 – 15:15 Break, Hall 1 & Hall 2, Moderated e-Posters, Theatres 1, 2, 3 & 4 15:15 – 16:15

15:15 – 16:15

15:15 – 16:15

15:15 – 16:15

15:15 – 16:15

15:15 – 16:15

15:15 – 16:15

15:15 – 16:15

15:15 – 16:15

15:15 – 16:15

15:15 – 16:15

International collaborative randomised trials in cardiac surgery: challenges and opportunities

Winner takes it all - YIA Finalists

The aortic valve exposed: from basic to experienced

Congenital videos

Type A dissection is always complicated

Escape the coffin

Transcatheter mitral and tricuspid valve procedures

Mitral valve surgery: when the neighbours matter

ERAS - turnkey order sets and deeper dives

Cutting-edge research in cardiac assist devices and perfusion techniques

Euromacs

16:15 – 16:30 Break, Hall 1 & Hall 2 16:30 – 17:30

16:30 – 17:30

16:30 – 17:30

16:30 – 17:30

16:30 – 17:30

16:30 – 17:30

16:30 – 17:30

16:30 – 17:30

16:30 – 17:30

16:30 – 17:30

16:30 – 17:30

ESC @ EACTS: the Heart Team in coronary artery disease and acute aortic syndromes

Cutting-edge perspectives of thoracic surgical oncology in the era of personalised medicine

Mechanisms and management: devices and support systems

Risk assessment for TAVI

Advances in aortic arch surgery - from AI to temperature

Congenital rapid Exploring future response 1 frontiers in atrial fibrillation ablating therapy

Expanding horizons in tricuspid valve surgery

How to use the radial artery

Mock exam session / EBCTS

QUIP

17:45 – 18:45

17:45 – 18:45

17:45 – 18:45

17:45 – 18:45

Paediatric thoracic surgery - an overview

Minimal invasive congenital heart surgery

Vascular graft infection – the silent epidemic

Right ventricle and tricuspid valve: a pending subject for cardiac surgeons

FRIDAY 11 OCTOBER Auditorium 1

Auditorium 2

Auditorium 3+4

Auditorium 6

Auditorum7

Auditorium 8

Room 3A

Room 3B

Room 3C

Room 5A

Room 5B

08:30 – 09:30

08:30 – 09:30

08:30 – 09:30

08:30 – 09:30

08:30 – 09:30

08:30 – 09:30

08:30 – 09:30

08:30 – 09:30

08:30 – 09:30

08:30 – 09:30

08:30 – 09:30

Surgical endocarditis bail-out strategies in multimedia

Innovations and outcomes in heart transplantation: from donor selection to post-transplant complications

Optimising recovery and outcomes: innovative approaches in cardiac surgery

Congenital Award

A deep dive into the frozen elephant trunk technique and related procedures

Thoracic rapid response 1

Standard of care operative management and future of septal myectomy

The post LAAOS III Era

Do not underestimate anatomy in mitral disease

Video-session on minimally invasive aortic valve replacement

Transformative perfusion approaches in aortic surgery Joint EACTS / EBCP session

09:30 – 10:00 Moderated e-Posters, Theatres 1, 2, 3 & 4

16

10:00 – 11:00

10:00 – 11:00

10:00 – 11:00

10:00 – 11:00

10:00 – 11:00

10:00 – 11:00

10:00 – 11:00

10:00 – 11:00

10:00 – 11:00

10:00 – 11:00

10:00 – 11:00

Late breaking science: aortic valve disease

Interactive MDT

Navigating excellence: insights from the sky to the OR

Advancements in CABG

EACTS/STS session: how did the 2023 EACTS/STS aortic guidelines change your practice? A cased-based discussion by the experts

Congenital rapid Minimally response 2 invasive mitral surgery: how to learn - how to teach

Expanding horizons in robotic mitral valve surgery

Heart transplantation and LVADs in 2024 – an update

Controversies in robotic thoracic surgery – balancing risk and reward

Promoting big trials

EACTS DAILY NEWS

Acquired Cardiac Disease

Vascular Disease

Thoracic Disease

General Interest

SCIENTIFIC PROGRAMME

Congenital Disease

FRIDAY 11 OCTOBER Auditorium 1

Auditorium 2

Auditorium 3+4

Auditorium 6

Auditorum7

Auditorium 8

Room 3A

Room 3B

Room 3C

Room 5A

Room 5B

11:15 – 12:00 Presidential Address, Auditorium 1 12:00 – 13:45 Lunch, Exhibition, Satellite Symposia, e-Poster discussions, Hall 1 & 2 13:45 – 14:45

13:45 – 14:45

13:45 – 14:45

13:45 – 14:45

13:45 – 14:45

13:45 – 14:45

13:45 – 14:45

13:45 – 14:45

13:45 – 14:45

13:45 – 14:45

13:45 – 14:45

Scalpel scars – nightmares untold

Giants in thoracic surgery

Highlights of the 2024 Innovation Summit – part 1

Avoiding stenoses in the pulmonary arteries in surgery for congenital heart disease

Unresolved questions in CABG

Advances in aortic root surgery

Walking together in lone AF ablation and beyond - EHRAEACTS joint session

Knowledge every cardiac surgeon should have prior to performing a CABG: clarifying the concepts of coronary ischemia, reversibility and regional myocardial perfusion

The ideal aortic valve substitute in a 50-year-old patient is a…

Accelerating minimally invasive mitral valve surgery

Cutting-edge techniques in HOCM and VSD surgery

14:45 – 15:15 Break, Hall 1 & Hall 2, Moderated e-Posters, Theatres 1, 2, 3 & 4 15:15 – 16:15

15:15 – 16:15

15:15 – 16:15

15:15 – 16:15

15:15 – 16:15

15:15 – 16:15

15:15 – 16:15

15:15 – 16:15

15:15 – 16:15

15:15 – 16:15

15:15 – 16:15

Late breaking science: coronary artery bypass grafting and perioperative care

Video session - mastering advanced surgical procedures: techniques and insights

Highlights of the 2024 Innovation Summit – part 2

Brain matters – examining neurodevelopmental outcome

Taking care of patients with heritable thoracic aortic disease - from pregnancy to aortic arch repair

Thoracic rapid response 2

Connecting the dots: right heart failure, pulmonary hypertension, and tricuspid valve dysfunction unraveled

The RITA under fire

Advanced strategies and management in complex endocarditis cases

A glimpse into the future solutions of mitral valve surgery

The aortic valve unravelled

16:15 – 16:30 Break, Hall 1 & Hall 2 16:30 – 17:30

16:30 – 17:30

16:30 – 17:30

16:30 – 17:30

16:30 – 17:30

16:30 – 17:30

16:30 – 17:30

16:30 – 17:30

16:30 – 17:30

16:30 – 17:30

16:30 – 17:30

Mitral repair at its best: a video tour

Optimising CABG outcomes: setting new standards

EACTS/AATS Foundation Academic Excellence Award

Congenital miscellaneous II

Rethinking aortic arch repair – more physiologic operations minimising or avoiding circulatory arrest

New solutions for old problems in heart transplantation

Lung volume reduction interventions for emphysema

ERAS Cardiac/ STS expert consensus for perioperative care

Translational research and surgical science

TAVR or SAVR? Surgical challenges in life-time management

Challenges in thromboembolic pulmonary hypertension

SATURDAY 12 OCTOBER Auditorium 1

Auditorium 2

Auditorium 3+4

Auditorium 6

Auditorum7

Auditorium 8

Room 3A

Room 3B

Room 3C

Room 5A

Room 5B

08:30 – 09 :30

08:30 – 09 :30

08:30 – 09 :30

08:30 – 09 :30

08:30 – 09 :30

08:30 – 09 :30

08:30 – 09 :30

08:30 – 09 :30

08:30 – 09 :30

08:30 – 09 :30

How to get the best results in complex CABG populations

From incision to emission – a sustainable future

Nightmares

Complicated type A dissection – “It’s all about malperfusion!”

Thoracic rapid response 3

Mastering mechanical circulatory support: all you need to know

Life beyond P2

Elevating cardiac care in 2024: new EACTS/ EACTAIC/EBCP guidelines for cardiopulmonary bypass and EACTS position on prophylactic temporary mechanical circulatory support

Pre-Trainee session

What is happening in perfusion? joint EACTS / EBCP session

09:30 – 10:00 Moderated e-Posters, Theatres 1, 2, 3 & 4 10:10 – 11:00

10:10 – 11:00

10:10 – 11:00

10:10 – 11:00

10:10 – 11:00

10:10 – 11:00

10:10 – 11:00

10:10 – 11:00

10:10 – 11:00

10:10 – 11:00

10:10 – 11:00

What a heart team surgeon needs to know about TAVI

Thoracic surgery techniques: the broad landscape of localisation and resection techniques for non-palpable pulmonary lesions

Francis Fontan Fellowship

Exploring ethical dilemmas in congenital heart disease

Hereditary Thoracic Aortic Disease (HTAD) – finding a way through the maze

2024 EACTS perioperative medication guidelines

Mitral and concomitant AF. Walking hand in hand

Current controversies in short term MCS

Key messages from current myocardial revascularisation guidelines and joint methodologies for enhancing worldwide healthcare standards

2024 EACTS/ EACTAIC patient blood management guidelines in adult cardiac surgery in collaboration with EBCP

Multidisciplinary teams working to keep patients at the centre of care

11:05 – 12:35

11:05 – 12:35

11:05 – 12:05

11:05 – 12:05

11:05 – 12:05

11:05 – 12:35

Trial update session

Screening of lung cancer in the twenties

Preventing failing Fontan

Fate of the aortic root in type A aortic dissection - to root or not to root

Cardiac surgery intersociety alliance

Nursing & Allied Health Professionals abstracts

12:35 – 13:20 Closing Plenary, Auditorium 1 Keynote Lecture: “How I survived impossible odds” – Roberto Canessa EACTS Awards Ceremony Farewell Drinks Reception from 13:20

For detailed programme and break times please refer to the EACTS App. Issue 2 Friday 11th October

17

INNOVATION

ADVANCING A CULTURE OF INNOVATION To stimulate “out-of-the-box” thinking EACTS has already organised two Innovation Summits in 2023 and 2024. Participants included cardiothoracic surgeons and highly recognised specialists from various scientific fields including engineering, computer science, biochemistry, genetics, physics and economics. The Summits facilitated an intensive exchange of ideas and enabled delegates to form new collaborations.

These Innovation Summits marked the beginning of a new scientific format that enables individuals and interdisciplinary teams to work more intensively on key areas to improve the way we treat our patients.

The 2024 EACTS Innovation Summit included sessions on AI, robotic surgery, heart valves, extracorporeal circulation, single- and multi-organ repair and replacements, hibernation, lymphatics and glymphatics, and perioperative cellular protection. The very best abstracts are also being presented here in Lisbon.

Innovation Hub: embedding disruptive innovation As part of our efforts to increase engagement in disruptive innovation, EACTS has established the Innovation Hub which serves as the umbrella for all of EACTS’ work on innovation. The Hub will enhance and intensify the application of upcoming innovations for improved cardiothoracic surgical treatments and support the creation of novel innovations by overseeing a peer network, research support and awarding new innovation grants.

Innovation Committee: championing innovation The Innovation Committee, chaired by Friedhelm Beyersdorf and Mark Hazekamp, brings together cardiothoracic surgeons and experts from outside our field to facilitate communication and support the development of new ideas and technologies that will ultimately benefit patients.

The new Innovation Committee is starting with a clear focus on six key areas: • Artificial Intelligence (AI) and (Augmented) Virtual Reality in Cardiothoracic Surgery • Robotic-Assisted Cardiothoracic Surgery • Heart Valves of the Future • Extracorporeal Circulation (cardiopulmonary bypass (CPB), extracorporeal membrane oxygenation (ECMO), extracorporeal life support (ECLS)), Singleand Multi-Organ Repair and Replacement

• Peri-Operative Cellular Protection • Lymphatics and Glymphatics, and – separate from everything else - Wild Cards To achieve practical results in these areas and support investigators and inventors, EACTS plans to establish a “how to start a startup” group. This group will foster innovative culture, harness cutting-edge technology, prioritise patient needs and promote experimentation with disruptive ideas that drive meaningful change.

Funding to support your research We are excited that EACTS members will be able to apply for new innovation and research grants. Financial support will be backed by access to resources, expertise from a dedicated expert network with a strong emphasis on meeting patient needs. These awards will be introduced to support truly extraordinarily innovative projects, further encouraging groundbreaking advancements.

The power of disruption

Innovation Committee Innovation Summit

Innovation Fund

Hub Research support

Innovation Strategy Peer network

Friedhelm Beyersdorf, Chair of the Innovation Committee, said, “We are currently experiencing a significant wave of advancements across various scientific fields, offering unprecedented opportunities to elevate our specialty. Disruptive technologies such as AI, synthetic biology, nanotechnology and robotics are poised to further revolutionise the field.

“By integrating emerging scientific innovations into clinical practice, cardiothoracic surgery is set to enter a transformative era, improving patient outcomes and expanding treatment possibilities for previously untreatable conditions and simultaneously reduce morbidity. Through the launch of these new initiatives EACTS is actively engaging with these developments to unlock the vast opportunities and improvements they offer for our patients.”

As part of our efforts to increase engagement in disruptive innovation, EACTS has established the Innovation Hub which serves as the umbrella for all of EACTS’ work on innovation.

INNOVATION

18

EACTS DAILY NEWS

INNOVATION

THE HIGHEST RANKED ABSTRACTS FROM THE EACTS INNOVATION SUMMIT 2024.

ABSTRACT surgeon, robotic mitral valve repair is safe and achieves similar repair rates and long term valve durability compared to both conventional and port-access mitral valve repair.

Meindert Palmen Leiden University Medical Centre, Netherlands

The initial learning curve for robotic mitral valve repair can be overcome through adherence to a tailored and team based training programme, the creation of a dedicated robotic team and by introducing proctoring. Importantly, EACTS has expressed its support for robotic cardiac surgery in Europe. This endorsement presents an opportunity for European cardiac surgeons to start or Figure 1: Manual robotic controls located in the surgeons console

revive their robotic programmes, fostering innovation, expanding our surgical armamentarium and improving current surgical practice. For the best results, we would have access to a training and proctoring programme, ideally endorsed by EACTS, for starting centres. In the long term, as technology continues to advance, robotic cardiac surgery may serve as a foundation and stepping stone for or future developments in the surgical treatment of valvular heart disease.

Figure 2: Overview of the robotic OR suite during robotic mitral valve repair

Robots in Mitral Valve Surgery Robotic mitral valve repair is an innovative, minimally invasive surgical approach that combines unparalleled dexterity with 3D vision, allowing surgeons to perform minimally invasive mitral valve repair (also combined with atrial arrhythmia surgery and tricuspid valve repair) without compromising surgical technique, while reducing surgical trauma. In the short term and in a selected patient population, these benefits result in less blood loss, a lower risk of post-operative complications, shorter stays in hospital and faster recovery times compared with conventional surgery. When performed by an expert mitral

ABSTRACT drug release triggered by ultrasonic (US) stimulation from outside the body.

Rui J. Cerqueira Hospital São JoãoPorto, Portugal

Development of the device will be based on new smart multifunctional materials: electrospun piezoelectric fibres.

The core ambition of REBORN is to create a multifunctional and intelligent cardiac patch designed to prevent heart failure in patients who have survived an acute myocardial infarction.

The project, which began in January 2023, is funded by the European Health and Digital Executive Agency with a significant contribution of over €4 million and is set to run for 48 months. We have been able to produce the first prototypes of this device, and we are now testing its functionality in vitro and in vivo, in the pre-clinical setting.

We are also exploring the scalability of the manufacturing process of the REBORN Patch.

Piezoelectric patch enriched with smart ultrasound-responsive nanocarriers for controlled drug release for myocardial regeneration The REBORN project will aim to use smart and multifunctional biomaterials to deliver a new medical device in the form of a cardiac patch, to be applied to the heart in order to stimulate and support local heart tissue remodelling.

The piezoelectric patch will electromechanically couple with the heart and deliver anti- inflammatory, anti-fibrotic and cardiomyocyte proliferative factors on demand, with

ENCES

ITS

ER

M

CON

F

CALL FOR ABSTRACTS

& SUM

EACTS 3rd Innovation Summit

www.rebornproject.eu

The EACTS Innovation Summit 2025 invites surgeons, engineers, innovators, researchers, and scientists active in or even outside the field of Thoracic and Cardiovascular Surgery to submit abstracts to the upcoming Innovation Summit 2025.

Abstract submission open Tuesday 15 October 2024.

Issue 2 Friday 11th October

19

THE 38TH EACTS ANNUAL MEETING

NAVIGATING

NEW HORIZONS Innovate, Discover, Educate

EXHIBITION FLOOR PLAN

HALL 1 Theatre 1

101 102

142

103

143 161

104 105 106

121 122 123

144 145

162

124 125 126

146 147

163

148 149 127 128 129

108 109

130 131

152 153

132 133

154 155

113 111

156 157 134 135

158 159

136 137 114 115 116 117

138

Thursday 10 October 09:00 - 18:30, Welcome Reception 17:00 - 18:30 Friday 11 October 09:00 - 17:00

201 202

217

139 Theatre 2

140

BAR

Saturday 12 October 09:00 - 12:00

Theatre 3

150 151

112 110

EXHIBITION OPENING TIMES:

HALL 2

141

203 204 205 206 207

218

219

208 209 210

220

212 213 214 215

216

221

223 224 225 226 222

228

230

229

235 232

Theatre 4

227

236 237

20

EACTS DAILY NEWS

231

238 239 240 241 242 243 244 245

233

234

246 247 248 249 250 251

252

ANNUAL MEETING EXHIBITOR NAME

BOOTH NUMBER

EXHIBITOR NAME

BOOTH NUMBER

39th EACTS Annual Meeting

162

Healthium Medtech Limited

131

3-D Matrix UK Limited

121

HEMONART A.Ş.

146

Abbott

229

IDOL HASTANE ÜRÜNLERI SAN.VE TIC.A.S.

224

ABIOMED Europe GmbH

219

Integra LifeSciences

124

Advancis Surgical

161

Intuitive Surgical SARL

114 & 116

Alexion AstraZeneca Rare Disease

139

i-SEP

236

American Association for Thoracic Surgery (AATS)

104

Kapp Surgical Instrument, Inc.

141

Andocor NV

111

KLS Martin Group

203

Arthrex GmbH

132 & 133

Artivion, Inc.

217

LSI Solutions

227

Asian Society for Cardiovascular and Thoracic Surgery

101

Medela AG

201 & 202

AtriCure Europe B.V.

234

Medistim ASA

228

Becton Dickinson UK Limited

210

Medtronic

232

Berlin Heart GmbH

239 & 240

LivaNova

Meril Life Sciences Private Limited

149 & 151

241 & 242

BFW, Inc.

152

NeoChord, Inc.

243

BioCer Entwicklungs-GmbH

123

NEOS SURGERY

207

BIOMED® surgical

154

OpInstruments GmbH

Braile Biomédica

142

OSYPKA AG

209

Cardio Medical GmbH

237

Peters Surgical

230

CARMAT

216

PRRI Cardiothoracic / ISMICS / HVS & ICC

138

Corcym S.r.l.

218

Qualiteam s.r.l.

208

CTSNet.org

103

REDAX Spa

156 & 158

CUI INTERNATIONAL LIMITED

148

RenalGuard Solutions, Inc.

122

CytoSorbents Europe GmbH

140

Scanlan International, Inc

153, 155, 157 & 159

De Soutter Medical

163

Sinapi biomedical (Pty) Ltd

134

Delacroix-Chevalier

136 & 137

SmartCanula sàrl

135

Dendrite Clinical Systems Ltd

212 & 213

SpectroCor

127

STS-The Society Of Thoracic Surgeons

102

Sunoptic Technologies

144

Terumo Aortic

233

Designs for Vision Dr. Franz Köhler Chemie GmbH

223 205 & 206

EACTS-The European Association For CardioThoracic Surgery

221

Edwards Lifesciences

235

em-tec GmbH

150

enableCV

130

Eurosets s.r.l.

231

Exstent Ltd

252

FEHLING INSTRUMENTS GmbH & Co. KG FIAB Spa Fresenius Medical Care Deutschland GmbH

225 & 226 113 108 & 109

GEISTER Medizintechnik GmbH

220

Genesee BioMedical Inc

250

Getinge

222

Grena Ltd

214 & 215

Terumo Cardiovascular

105 & 106

246 & 247

Tianjin Plastics Research Institute Co Ltd (TPRI)

143

Tianjin Welcome Medical Equipment Co., Ltd.

145 & 147

tisgenx, Inc.

251

Transonic Systems, Inc.

204

USB Medical, Ltd.

125

Vivostat A/S

238

Waston Medical Co., Ltd

244 & 245

Wexler Surgical, Inc.

128 & 129

x-cardiac GmbH

126

Xenosys Co., Ltd. & R&D Surgical Ltd.

248 & 249

Zimmer Biomet

115 & 117

Issue 2 Friday 11th October

21

EACTS TV

Your guide to what's on

TUNE IN

Watch live and recorded content from this year's Annual Meeting on EACTS TV. Educational and entertaining, EACTS TV features compelling panel debates, Annual Meeting highlights and interviews with the world’s leading cardiothoracic surgeons.

FRIDAY 11 OCTOBER TIME

22

PROGRAMME

SATURDAY 12 OCTOBER PANELLISTS

09:15 - 09:30

On the Pulse: Exploring the Exhibition

09:30-09:50

The Daily Preview – Today at the Annual Meeting

Florian Schoenhoff Jürgen Hörer Nabil Hussein

10:00-10:20

Shaping the Future of Aortic Dissection: The Power of the Patient's Voice

Cristina Ruizsegria Catherine Fowler Bob Harris

10:30-10:55

Preview: The CT Surgery Resident Showdown

Juan Grau Nabil Hussein Patrick Myers Richard Milton

11:00-11:15

CT Surgery in LMICS

Carlos Mestres Charles Yankah Emily Farkas

11:15-12:15

Live broadcast: Presidential Address

Franca Melfi

12:15-13:00

CT Surgery Resident Showdown: Live European Final!

Finalists: • Marco Gemelli and Francesco Bertelli - University of Padova • Riccardo Orlandi and Giovanni Mattioni - University of Milan • Joeri Van Puyvelde and Katrien Vandendriessche - University Hospitals Leuven

13:15-13:30

In focus with… Volkmar Falk – Incoming Volkmar Falk EACTS President

13:30-13:45

The Big Debate - Artificial Intelligence & Augmented Reality

14:45-15:10

Evgenij Potapov Next month in Prague – Presentations Gloria Färber of new pumps and Ideas from the world Julia Riebandt of MCS Pia Lanmüller

15:15-16:15

Session broadcast: Highlights of the 2024 Innovation Summit – Part 2

16:15-16:30

The Big Debate - Cardiology & Cardiothoracic Guidelines

Faisal Bakaeen Jeroen Bax Milan Milojevic Volkmar Falk

16:35-16:45

EACTS 3rd Innovation Summit (2025)

Friedhelm Beyersdorf Mark Hazekamp

16:45-17:10

Latin heart rounds live with EACTS

Victor Bautista Hernandez

17:20-17:40

Science Friction - The Daily Review

Filip Casselman Milan Milojevic Rafa Sádaba

EACTS DAILY NEWS

Juan Grau (host) Richard Milton (host)

Hazem Fallouh Tomaz Štupnik

TIME

PROGRAMME

PANELLISTS

09:15 - 09:30

On the Pulse: Exploring the Exhibition

Roy Sheppard

09:30-09:50

The Daily Preview – Today at the Annual Meeting

Jeroen Bax Richard Milton

10:00-10:15

Innovation in CT Surgery

Can GollmannTepeköylü Joe Bavaria Volkmar Falk

10:20-10:30

Previewing the 2025 Annual Meeting

Volkmar Falk Patrick Myers

10:35-10:55

EACTS Award Winners 2023 - One year on

Debora Brascia Giuseppe Comentale Justin Ren

11:00-12:30

Live broadcast: Trial Update Session

12:30-13:20

Live broadcast: Keynote Lecture & Awards Ceremony

R. J. Canessa Urta

LIVE FINAL

RESIDENT SHOWDOWN

12:15 - 13:00

Two-person teams of residents will face off today in the final of the CT Resident Showdown. Visit the EACTS TV Studio and watch live as the teams compete in the ultimate test of cardiothoracic knowledge.

Finalists: • Marco Gemelli and Francesco Bertelli University of Padova • Riccardo Orlandi and Giovanni Mattioni University of Milan • Joeri Van Puyvelde and Katrien Vandendriessche - University Hospitals Leuven

The winning team will go on to compete against the winning North American team at the STS Annual Meeting in 2025 where the CT Surgery Masters World Champions will be crowned.

Find out more about this year’s contestants in a preview of the CT Residents Showdown on EACTS TV at 10.30.

THE INCIDENCE OF MAJOR BLEEDING AFTER CORONARY ARTERY BYPASS GRAFTING SURGERY CAN BE UP TO

52.9 %

1

How do you recognize patients at risk?

Meet us at booth no. 80 in hall X1 and learn more about it

1 Stone GW, et al. American Heart Journal 2012;163(3): 522-529. ISSN 0002-8703, Medela AG Lättichstrasse 4b 6340 Baar, Switzerland www.medela.com

LIVE FINAL 12:15 - 13:00 LIVE ON EACTS TV

RESIDENT SHOWDOWN

LEARNING LABS

LEARNING LABS Hands-on guidance from the experts

Take advantage of the invaluable opportunity to train with some of the world’s best cardiothoracic surgeons at the EACTS Learning Lab. These specialist hands-on workshops are designed to advance your technical abilities and include wetlabs, drylabs, simulation and practical sessions.

You will gain practical experience using the latest devices, practice on simulators and interact with expert faculty and industry proctors. EACTS Learning Lab sessions are available for just an additional €75 each. Spaces are limited and offered on a firstcome, first served basis. Don't miss out—book today to guarantee your opportunity.

EACTS LEARNING LAB SCHEDULE Friday 11 October 09:00 – 11:00

Congenital – The Senning Procedure

09:00 – 11:00

Endoscopic Dry Lab Training

12:15 – 14:15

Mitral Valve

12:15 – 14:15

Endoscopic Dry Lab Training (Aortic)

15:00 – 17:00

Segmentectomy and Airway reconstruction

15:00 – 17:00

Endoscopic Dry Lab Training

Saturday 12 October 09:00 – 11:00

Transcatheter

09:00 – 11:00

Endoscopic Dry Lab Training

INDUSTRY LEARNING LABS

24

Company

Booth Number

Join our industry partners to explore new technologies and try different techniques and approaches at this year’s industry learning labs.

AtriCure

234

Edwards Lifesciences

235

Visit their booths in the Exhibition Hall to find out more.

Getinge Deutschland GmbH

222

Medtronic

232

Peters Surgical

230

Terumo Aortic

233

EACTS DAILY NEWS

SPONSORED BY ATRICURE

ADVANCES IN ATRIAL FIBRILLATION TREATMENT

Awareness amongst surgeons of the importance of treating atrial fibrillation (AF) – either with concomitant surgery or as a standalone procedure – is still relatively low with only a small percentage of patients receiving this type of treatment.

Thorsten Hanke, Director of the Cardiac Surgery Clinic at the Asklepios Clinic HamburgHarburg, Germany, discusses how advancements in the treatment of atrial fibrillation and the introduction of the new ESC guidelines developed in collaboration with EACTS, for the management of atrial fibrillation could positively impact patient outcomes.

What are the main reasons for the under treatment of surgical AF in Europe, and what does this means for patients?

Atrial fibrillation clinically is not just a rhythm disorder or an endocardial cushion defect. It is clear from recent data that atrial fibrillation is a malignant disease that must be treated. It can have an enormous impact on a patient’s quality of life and health including increased risk of stroke, depression, dementia, heart failure and numerous readmissions to the hospital.

However, a large proportion of the surgical community does not see the necessity of treating atrial fibrillation in a cardiac surgery procedure. For example, in Germany only 17% of the patients being in AF are being treated concomitantly, despite being on the table in the operating room. Therefore, we are missing a big chance to improve patient outcomes significantly.

Treating AF has a huge impact on patient outcomes. Large registry data from Poland shows the survival benefits of treating patients who are in AF, irrespective of the procedure, whether it is mitral valve procedures, CABG or aortic valve procedures.

One of the largest RCT in cardiac surgery, the LAAOS III study, showed that if you close the left atrial appendage in patients with AF during heart surgery, which by the way is an obligatory part of the Maze procedure, there is a significant impact on stroke reduction and on systemic emboli.

In my view another reason for the under treatment of surgical AF is the low interest in electrosurgery. It is a fairly straightforward procedure, but the results are not immediate. Patient monitoring is required for at least three months and maybe even for a patient’s lifetime in order to assess the impact of the procedure.

How have advancements in therapies such as concomitant ablation and LAA exclusion impacted the treatment of AF patients?

There have been advances in techniques and devices that support surgeons in the treatment of AF and deliver better outcomes for patients.

The use of alternative energy forms, such as cryogenic and bipolar RF, have facilitated the procedure enormously.

In larger registries, an AF ablation has shown to reduce mortality with no additional risk to the operation, even in patients with a reduced left heart function.

Different devices such as AtriClip have been specifically designed for the only purpose of excluding the LAA and are indicated to reduce the risk of stroke originated from the Left Atrial Appendage

There are new solutions on the market for treating AF, for example, the Encompass clamp used in the Boxx procedure. How are these devices supporting better patient outcomes?

The original Cox Maze 4 procedure is biatrial, creating lines with either cryo or RF energy. This is a time-consuming procedure which requires opening the heart. Adding another procedure during surgery could be a contributing factor to why some surgeons are reluctant to treat AF. The introduction of the Encompass clamp has positively impacted the treatment of AF patients, enabling surgeons to create a box lesion without opening the left atrium. The box enables surgeons to isolate the pulmonary veins and the posterior wall, which is an important anatomical structure with respect to AF perpetuation, and thus delivers better outcomes for patients whilst making the procedure easier for surgeons. As a result, we have a very robust therapy that prevents a lot of atrial fibrillation in these patients.

The new guidelines also address standalone procedures together with the left atrial appendage closure (2a C indication).

Now, when surgeons are implementing a standalone AF programme, concomitant LAA closure should be taken into consideration. This additional surgical procedure then “rounds up” the 360° treatment option for patients being transferred for standalone surgical AF ablation.

The guidelines also set out the need to use a transesophageal echocardiography in the OR when treating atrial fibrillation in order to check for thrombus formation in the left atrial appendage before skin incision.

(1 C). I'm quite convinced this is already commonplace but it emphasises the importance of LAA surveillance before surgery, and this is supported by the Class 1C indication.

I am hopeful that referring physicians and cardiologist will now require the surgeons to insist on the additional treatment of AF in light of the convincing data and recommendations outlined in the guidelines.

The Encompass clamp used in the Boxx procedure has a success rate of approximately 70% and more or, alternatively, other RF clamps can be used to create a box lesion to perform the ABC technique.

The 2024 ESC guidelines recommend closing the left atrial appendage during concomitant surgery. This is set out as a class 1B indication. So, closing the LAA, for example, with a clip in order to complete the BOXX procedure to treat AF and prevent a stroke. The Encompass clamp is a fast and easy technique one can use during this procedure. With no further need to open the left atrium, the threshold for treatment has been set lower.

The 2024 ESC guidelines for the management of atrial fibrillation, developed in collaboration with EACTS, introduced several new approaches and treatment. How will these recommendations change the landscape for surgeons treating AF?

Thorsten Hanke is also the Chair of the EACTS Arrythmia Task Force.

AtriClip® Flex•V

New to the 2024 guidelines, the concomitant surgical ablation is a class 1a indication for mitral procedures and 2a for non-mitral procedure.

With this, the 2024 guidelines include a class 1B indication to close the left atrial appendage during concomitant surgery especially in patients with atrial fibrillation. This is a huge step for AF patient safety and something we are very proud of.

Isolator® Synergy™ EnCompass® Clamp

For patients being in persistent AF, there now is a 2a A indication to treat atrial fibrillation as a first step therapy. When performing hybrid AF procedures, the electrophysiologists are now able to work hand in hand with the surgeon and being able to control the surgical procedures in the following EP ablation assessment. Thus, the outcome of surgical AF ablation will increase.

Issue 2 Friday 11th October

25

EACTS ACADEMY

2024

UPCOMING COURSES Robotics Revascularisation Training

28 – 29 October, Leuven, Belgium

Congenital Imaging Webinar

5 November, Online

8th EACTS Mechanical Circulatory Support Summit

7 – 9 November, Prague, Czech Republic

Thoracic Surgery meets Neurology: Myasthenia Gravis

13 November, Online

Navigating the Maze

15 – 16 November, Barcelona, Spain

Congenital Skills Course

18 – 19 November, Rome, Italy

Endovascular Aortic Repair Webinar

21 November, Online

EACTS Emerging Leaders Masterclass: Leading Effectively with Impact & Insight

26 – 27 November, Windsor, UK

Atrial Fibrillation Webinar II: From Theory to Praxis

28 November, Online

EACTS/STS/LACES Latin America Cardiovascular Surgery Conference

5 – 7 December, Buenos Aires, Argentina

Chronic Thromboembolic Pulmonary Hypertension: PEA and the New Kids on the Block

11 December, Online

EACTS/Intuitive Discovery Course

16 December, Amsterdam, The Netherlands

For the most up-to-date course details visit www.eacts.org Courses and dates subject to change

26

EACTS DAILY NEWS

EACTS ACADEMY

EACTS ACADEMY

UPCOMING EVENTS

For over a decade, the EACTS Academy has proudly been at the forefront of global cardiothoracic surgical education, delivering high-quality training to empower surgeons and cardiothoracic teams. Our education offer continues to go from strength to strength with an ever-increasing number of courses available for all levels of experience.

ROBOTICS REVASCULARISATION TRAINING 28 – 29 October | Leuven, Belgium

This two-day course balances live stream surgeries, simulators for robotic controls and cadaver training & interactive lectures.

Attendees will have an opportunity to perform challenging procedures on simulators for robotic controls including a beating heart anastomoses under the guidance of experts in the field as well as cadaver training for thoracotomy approach and stabilisation.

Running parallel with the hands-on sessions, experts will give inspiring presentations exploring the the next steps for revascularisation procedures and what is needed to get TECAB in Europe.

This level 2 course is perfect for surgeons who are keen to expand their knowledge in robotic procedures and work alongside a proctor in preparation to start up a robotics programme in their home centre.

"The Robotic Revascularisation Training course is an excellent (if not vital) preparation before performing surgery on an actual patient. It taught us the important steps for robotic midcab, from docking up to the harvest of the IMA. The course provided us with a close to the real thing simulation, in which you can learn and "make mistakes" in a very safe environment.

It showed us the little things to avoid to prepare for a safe and successful surgery.

REGISTRATIONS NOW OPEN In June 2025, surgeons with an interest in aortic diseases will come together in the beautiful city of Prague for three days of education, discussion and networking at the 3rd EACTS Aortic Forum.

The highly anticipated programme features some of the most important and influential voices in the field of aortic surgery. Highlights include sessions devoted to the pathology of the aortic root with a special focus on the latest advances in aortic valve repair and in the Ross Operation, as well as discussions on the pathology of the ascending aorta and arch, in its acute or chronic forms.

Ruggero De Paulis, Aortic Forum Taskforce Chairman said, “The recent EACTS/STS Guidelines for diagnosing and treating acute and chronic syndromes of the “aortic organ” have recently highlighted the importance of these pathologies for an extremely large group of patients.

Interactive sessions will guarantee a lively discussion and interaction with the whole faculty as we explore topics such as the current controversies for the best treatment of each individual aortic pathology. We are proud to offer this exciting opportunity to our members and colleagues across the world. We look forward to seeing you in Prague next year.”

What past attendees say about the Aortic Forum

“Amazing meeting, discussed with a lot of legends in my field and learnt from them during these conversations, their tricks come from experience, and you cannot find them written in the books!”

"We will soon be launching our robotic cardiac surgery programme in the Philippines. The course has given us confidence the we can perform the surgery safely."

Ramir Pablo and Marvin Martinez past course participants

AORTIC VALVE REPAIR: A STEP-BY-STEP APPROACH An EACTS technical course on aortic valve repair March 19-21, 2025 | Paris, France

• lectures on echocardiographic assessment of the aortic valve and root, evidence for aortic valve repair, guidelines and indications, repair in aortic dissections, paediatric aortic valve repair, and alternatives to repair including the Ross procedure will be covered by an esteemed international faculty.

EMMANUEL LANSAC Course Director; La Pitié Salpétrière Sorbonne University Hospital, Paris, France This Level 3 EACTS course offers attendees a deep dive into a standardised and reproducible approach to aortic valve repair. This will include the rationale, physiological sizing and insertion techniques for incorporating an external aortic annuloplasty ring as part of any repair procedure.

The course covers • in-depth training of aortic valve repair from valvesparing root replacement (for root aneurysms) to isolated aortic valve repair (for isolated aortic insufficiency).

• Repair techniques for tricuspid, bicuspid and unicuspid valves covered in step-by-step detail.

• how to repair different valve morphologies and aortic phenotypes through s combination of technical lectures combined with 4 full live surgeries and further pre-recorded live-in-a-box video sessions on different lesion sets

The programme will also include a ‘failure session’, in which attendees will discuss cases all the way from echo analysis to surgical repair, learning how to identify predictors of repair failure as well as the bailout techniques available to them when such situations arise. Lectures on how to set up a new aortic valve repair programme will also be given.

The 3rd day of the course will provide wet lab training, allowing attendees to practice what they have learned on cadaveric hearts within the historical laboratory of anatomy in Paris, du Fer à Moulin. There will be an international faculty to supervise, support and provide hands-on teaching during this session.

Who is this course aimed at?

Cardiac surgeons and echocardiographers (cardiologists and anaesthetists) who are willing to start, or are already part of, a valve-sparing aortic root replacement and aortic valve repair programme.

Advanced residents interested in the field of valve repair are also welcomed.

Issue 2 Friday 11th October

27

E-POSTERS

E-POSTERS ENJOY EVEN MORE SCIENCE AT THE 38TH EACTS ANNUAL MEETING

FRIDAY 11 OCTOBER - MODERATED E-POSTERS

09:30 - 10:00

14:45 - 15:15

Acquired Cardiac Moderated e-Posters - Heart Failure

Theatre 1

Vascular Moderated e-Posters - Endovascular Aortic Treatment

Theatre 2

Congenital Moderated e-Posters

Theatre 3

Thoracic Moderated e-Posters

Theatre 4

Acquired Cardiac Moderated e-Posters - Transcatheter

Theatre 1

Vascular Moderated e-Posters - Miscellaneous on aortic treatment and training

Theatre 2

Congenital Moderated e-Posters

Theatre 3

Thoracic Moderated e-Posters

Theatre 4

FRIDAY 11 OCTOBER - E-POSTER DISCUSSIONS

12:15 - 13:30

28

EACTS DAILY NEWS

e-Poster Discussion 5 - Miscellaneous (Acquired Cardiac)

Theatre 1

e-Poster Discussion 6 - Acquired Cardiac

Theatre 2

e-Poster Discussion 7 - Congenital

Theatre 3

e-Poster Discussion 8 - Thoracic

Theatre 4

E-POSTERS

SATURDAY OCTOBER - MODERATED E-POSTERS

09:30 - 10:00

Acquired Cardiac Moderated e-Posters - Mitral & Tricuspid Valve

Theatre 1

Acquired Cardiac Moderated e-Posters - Misc 2

Theatre 2

Congenital Moderated e-Posters

Theatre 3

Thoracic Moderated e-Posters

Theatre 4

Acquired Cardiac Disease Thoracic Disease Congenital Disease Vascular Disease

VIEW THE E-POSTERS DISCUSSION

VIEW THE MODERATED POSTERS

Issue 2 Friday 11th October

29

AWARDS 2025

SHERATON GRAND PARK LANE LONDON, UNITED KINGDOM IN COLLABORATION WITH

GLOBALCARDIOVASCULARAWARDS.COM

SATELLITE SYMPOSIA

Join experts as they discuss the latest clinical data, current and future approaches to patient care and much more in a wide range of satellite sessions hosted by industry.

SS 24

These sponsored programmes do not form part of the official Annual Meeting scientific programme.

FRIDAY 11 OCTOBER TIME

ROOM

12:15 - 13:30

Advancing Cardiac Surgery: Integrating Innovation and Patient-Centric Care in the next decade

Auditorium 8 (Interactive-RR)

12:15 - 13:30

Reconsidering current approaches to valve and LVAD therapies

Auditorium 3+4 (Interactive)

12:15 - 13:30

Hybrid Technologies: Many ways to simplify the arch with the Gold Standard

Room 5A, Pav 5

12:15 - 13:30

Reshaping Heart Recovery: Impella's Role in Improved Outcomes

Auditorium 6

12:15 - 13:30

New frontiers in mitral valve replacement

Auditorium 7

12:15 - 13:30

Structural Heart Innovation | Science, Clinical Experience & Landmark RCT

Auditorium 2

DOWNLOAD THE EACTS APP HERE

Issue 2 Friday 11th October

31

THE 39TH EACTS ANNUAL MEETING

DESIGNING THE FUTURE INNOVATE, DISCOVER, EDUCATE 8 - 11 October 2025 • Copenhagen, Denmark Join us next year in Copenhagen for the 39th EACTS Annual Meeting.

For 2025 you can expect robust debate and discussion led by global experts, the latest technological advances on display and an opportunity to share knowledge and socialise with your peers from around the world.